Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
| العنوان: | Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib |
|---|---|
| المؤلفون: | Jun Ohishi, Fumihito Hirai, Shotaro Sakisaka, Keiji Yokoyama, Kazuhide Takata, Yotaro Uchida, Takashi Miyayama, Hiromi Fukuda, Daisuke Morihara, Yasuaki Takeyama, Morishige Takeshita, Satoshi Shakado, Takashi Tanaka, Yi-Ling Ko, Ryo Yamauchi |
| المصدر: | Case Reports in Gastroenterology Case Reports in Gastroenterology, Vol 14, Iss 1, Pp 226-233 (2020) |
| بيانات النشر: | S. Karger AG, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Sorafenib, medicine.medical_specialty, medicine.drug_class, Single Case, Tyrosine kinase inhibitor, Malignancy, Gastroenterology, Tyrosine-kinase inhibitor, Peritoneum, Internal medicine, Pathology Result, medicine, Effective treatment, lcsh:RC799-869, neoplasms, Ectopic HCC, business.industry, medicine.disease, digestive system diseases, medicine.anatomical_structure, Hepatocellular carcinoma, Immunohistochemistry, lcsh:Diseases of the digestive system. Gastroenterology, business, medicine.drug |
| الوصف: | Ectopic hepatocellular carcinoma (HCC) is a rare malignancy, which manifests similar morphology and immunohistochemistry to intrahepatic HCC. Herein, we report a case of ectopic HCC in a 73-year-old male. The patient presented to our hospital with gradually progressing right lower abdominal pain, and enhanced computed tomography revealed multiple nodules in the peritoneum without intrahepatic mass. A diagnostic laparoscopy was performed, and the final pathology result confirmed that it was HCC. Additional laboratory tests showed elevated serum alpha-fetoprotein and protein induced by vitamin K absence-II (PIVKA-II) levels, suggesting our diagnosis. The patient received sorafenib, a tyrosine kinase inhibitor (TKI), for unresectable ectopic HCC. However, the tumor progressed, and because of tarry stools and hemorrhagic anemia, sorafenib was ceased after 7 months of therapy. One month after the cessation of sorafenib, the PIVKA-II level increased abruptly, and the patient died 1 year after diagnosis. The effective treatment for unresectable ectopic HCC is still unknown. Additional cases should be accumulated to determine the effect of TKI on ectopic HCC. |
| اللغة: | English |
| تدمد: | 1662-0631 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf6297caf72b2e6b1b675c38c2a48366 http://europepmc.org/articles/PMC7204886 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....cf6297caf72b2e6b1b675c38c2a48366 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16620631 |
|---|